Prosensa plans to refile Drisapersen for Duchenne MD - Prosensa

An investigation by Prosensa into the 2013 Phase III failure of its drug drisapersen for Duchenne Muscular Dystrophy suggests that "differences in baseline characteristics" may account for the result rather than a failure of the drug treatment itself.

The FDA has responded by saying the theory is "plausible but not conclusive" but is willing to condiser a new drug application. Prosensa now plans to refile the drug later in 2014. Glaxo Smith Kline which was partnered with Prosensa for the development of drisapersen withdrew from the partnership in January 2014.